Conclusion
Hypertrophic Cardiomyopathy secondary to Tacrolimus is an uncommon
potential life-threatening adverse effect described in solid organ
transplant receptors receiving this calcineurin inhibitor. Thus,
physicians should pay attention to patients receiving this drug,
especially when symptomatic patients are detected, in order to allow a
proper diagnosis of a potential cardiomyopathy and to establish
accurately its management and treatment, because it has been observed
that this adverse effect is reversible with its suspension.